EGFR and non-small cell lung carcinoma: Activating EGFR mutations may also upregulate TGF-β via EGFR–ERK1/2–p90RSK signalling, which could reduce CD8+ T cell infiltration and effector function in NSCLC, fostering a cold TME and resistance to PD-1 blockade [96].